SNAP Trial

This is a phase 2 placebo-controlled randomized controlled trial to determine whether the addition of ertapenem to cefazolin will increase the speed with which bacteria are cleared from the blood in methicillin-susceptible S. aureus bloodstream infections.

Ertapenem is a commonly used antibiotic for infections caused by extended-spectrum beta-lactamase producing Enterobacteraciae
Ertapenem is currently licensed in Canada for treatment of complicated skin and soft tissue infections commonly caused by S. aureus

What will the sub study involve - more information

Patients will be randomized to be given either ertapenem or a saline placebo
Patients will be monitored daily in hospital, or evaluated biweekly if up to 56 days post-discharge and once more on day 90 via email/phone/text
Consent will be obtained for access to patients' electronic medical records

Risks and benefits of taking part in this sub study

Risks:

Ertapenem can have a variety of side effects. However, these side effects and associated risk factors are well documented and will be accounted for before starting treatment
Side effects include anaphylaxis (rare and unlikely), seizures, and diarrhea associated with Clostridium difficile bacteria

Benefits:

This combination therapy treatment method can potentially reduce hospitalization time by speeding up the clearance of S. aureus from blood

Where will my sub study information be collected and stored?

Your personal information will be kept strictly confidential
All required data will be abstracted from the original clinical documents. This study will not keep a copy of the patient's clinical charts

What if I withdraw from this substudy?

You can withdraw from this sub study and/or from future use of your samples at any time, just notify a member of the SNAP study team

No follow up communications will occur, but we will request that any data collected up until withdrawal be retained for analysis. We will respect any requests from withdrawn patients to have their participant information removed from the study.
We will also request permission to confirm vital status of patients on Day 90, if agreeable